Pascal Deschatelets Selected Research

pegcetacoplan

10/2023	Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
1/2023	With complements: C3 inhibition in the clinic.
1/2023	Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
9/2022	Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
9/2022	Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
1/2021	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
11/2020	C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
1/2020	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pascal Deschatelets Research Topics

Disease

5	Hemolysis 01/2023 - 11/2020
5	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2023 - 11/2020
3	Chronic Disease (Chronic Diseases) 09/2022 - 11/2020
3	Fatigue 09/2022 - 11/2020
2	Geographic Atrophy 10/2023 - 01/2020
2	Macular Degeneration (Age-Related Maculopathy) 10/2023 - 01/2020
2	Injection Site Reaction 09/2022 - 01/2021
1	Rare Diseases (Rare Disease) 01/2023
1	Anemia 01/2023
1	Infections 01/2023
1	Nasopharyngitis 09/2022
1	Neoplasms (Cancer) 01/2022
1	Diarrhea 01/2021
1	Headache (Headaches) 01/2021
1	Thrombosis (Thrombus) 11/2020
1	Hematologic Diseases (Blood Diseases) 11/2020
1	Endophthalmitis (Ophthalmia) 01/2020

Drug/Important Bio-Agent (IBA)

8	pegcetacoplanIBA 10/2023 - 01/2020
6	Complement System Proteins (Complement)IBA 01/2023 - 11/2020
5	eculizumab FDA Link 01/2023 - 11/2020
2	Complement Inactivating AgentsIBA 01/2023 - 09/2022
1	salicylhydroxamic acid (SHAM)IBA 10/2023
1	PlacebosIBA 10/2023
1	ravulizumabIBA 09/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Complement C3 (C3 Complement)IBA 01/2020

Therapy/Procedure

6	Therapeutics 01/2023 - 11/2020
1	Injections 10/2023